About the Company
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE).
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AYLA News
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced ...
Ayala Pharmaceuticals Inc Ordinary Shares ADXS
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Advaxis Announces Definitive Agreement with Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. has agreed to sell its main assets, the AL101 and AL102 programs, to Immunome, Inc. for an ...
Immunome Strikes Deal to Acquire Ayala’s Drug Programs
Immunome, Inc. has entered into an agreement to acquire AL101 and AL102 programs from Ayala Pharmaceuticals, Inc., in a ...
IMNM Oct 2024 25.000 put
today announced the successful completion of its purchase of AL102 and related drug candidate AL101 from Ayala Pharmaceuticals, Inc. MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE ...
Concerns raised over Generika’s acquisition of North Luzon rival
The Philippine Competition Commission (PCC) said it launched an in-depth review of the proposed acquisition by the Generika ...
Ayala Pharmaceuticals Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Zeit Aktuelle Nachrichten 13:06 Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc ...
Loading the latest forecasts...